Epiomic Epidemiology Series: Migraine Forecast in 12 Major Markets 2018–2028

March 2018 | 54 pages | ID: E14712D0AEDEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Migraine in 12 Major Markets

Migraine is a common neurological disorder involving repeated headaches and associated phenomena. It is a leading cause of disability throughout the world. It has a multifactorial background (genetic, environmental, metabolic, hormonal, pharmacological) and triggers that vary between patients. However, it presents a common pattern of occurrence, with peak incidence in adolescence and peak prevalence in middle age. Recent research advances have helped to better determine the brain structures involved in migraine and observe physiological changes in patients with the disorder. These advances are the basis for studies of novel therapeutics and prophylactic approaches.

This report provides the current prevalent population for migraine across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of migraine patients, as well as the main symptoms of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main co-morbidities of migraine include:

• Hypertension (depending on the study)
• Mood disorders (anxiety, depression)
• Obesity
• Abdominal pain
• Emesis
• Cyclic vomiting syndrome (in children)
• Multiple sclerosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global migraine market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of migraine and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific symptoms on the prevalent population of migraine patients.
• Identification of migraine patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of migraine patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR MIGRAINE

FEATURES OF MIGRAINE PATIENTS

COMORBIDITIES OF MIGRAINE PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Diagnosis criteria of migraine with and without aura, and chronic migraine
Table 2. Factors associated with an increased risk for transformation/reversion of chronic migraine
Table 3. Prevalence of migraine, total (000s)
Table 4. Prevalence of migraine, males (000s)
Table 5. Prevalence of migraine, females (000s)
Table 6. Patients with migraine by classification, total (000s)
Table 7. Patients with migraine by laterality of pain, total (000s)
Table 8. Patients with definite migraine by type, total (000s)
Table 9. Patients with definite migraine with and without aura, total (000s)
Table 10. Patients with definite migraine by frequency per month, total (000s)
Table 11. Patients with definite migraine by MIDAS score, total (000s)
Table 12. Definite episodic migraine patients with nausea, total (000s)
Table 13. Definite chronic migraine patients with nausea, total (000s)
Table 14. Migraine patients with pain in the neck region, total (000s)
Table 15. Migraine patients with pain in the eye region, total (000s)
Table 16. Migraine patients with pain in the frontal region, total (000s)
Table 17. Migraine patients with pain in the temporal region, total (000s)
Table 18. Migraine patients with pain in the vertical region, total (000s)
Table 19. Migraine patients with pain in the occipital region, total (000s)
Table 20. Abbreviations and acronyms used in the report
Table 21. USA prevalence of migraine by 5-yr age cohort, males (000s)
Table 22. USA prevalence of migraine by 5-yr age cohort, females (000s)
Table 23. Canada prevalence of migraine by 5-yr age cohort, males (000s)
Table 24. Canada prevalence of migraine by 5-yr age cohort, females (000s)
Table 25. France prevalence of migraine by 5-yr age cohort, males (000s)
Table 26. France prevalence of migraine by 5-yr age cohort, females (000s)
Table 27. Germany prevalence of migraine by 5-yr age cohort, males (000s)
Table 28. Germany prevalence of migraine by 5-yr age cohort, females (000s)
Table 29. Italy prevalence of migraine by 5-yr age cohort, males (000s)
Table 30. Italy prevalence of migraine by 5-yr age cohort, females (000s)
Table 31. Spain prevalence of migraine by 5-yr age cohort, males (000s)
Table 32. Spain prevalence of migraine by 5-yr age cohort, females (000s)
Table 33. UK prevalence of migraine by 5-yr age cohort, males (000s)
Table 34. UK prevalence of migraine by 5-yr age cohort, females (000s)
Table 35. Russia prevalence of migraine by 5-yr age cohort, males (000s)
Table 36. Russia prevalence of migraine by 5-yr age cohort, females (000s)
Table 37. Japan prevalence of migraine by 5-yr age cohort, males (000s)
Table 38. Japan prevalence of migraine by 5-yr age cohort, females (000s)
Table 39. China prevalence of migraine by 5-yr age cohort, males (000s)
Table 40. China prevalence of migraine by 5-yr age cohort, females (000s)
Table 41. India prevalence of migraine by 5-yr age cohort, males (000s)
Table 42. India prevalence of migraine by 5-yr age cohort, females (000s)
Table 43. Brazil prevalence of migraine by 5-yr age cohort, males (000s)
Table 44. Brazil prevalence of migraine by 5-yr age cohort, females (000s)